Global skeletal uptake of technetium-99m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.

Autor: Frusciante, Vincenzo, Carnevale, Vincenzo, Scillitani, Alfredo, Zingrillo, Matteo, Dicembrino, Franca, Giannatempo, Giuseppe M., Ghiggi, Maria R., Minisola, Salvatore
Předmět:
Zdroj: European Journal of Nuclear Medicine; 1998, Vol. 25 Issue 2, p139-143, 5p
Abstrakt: Abstract. This study was carried out in order to investigate the possible detrimental effects on bone of levothyroxine (L-T[sub 4]) suppressive therapy in female patients who had undergone surgery for differentiated thyroid cancer (DTC). Twenty female (14 premenopausal and 6 postmenopausal) patients receiving L-T[sub 4] suppressive therapy for DTC were studied. The sample was selected in such a way as to avoid factors influencing bone metabolism other than L-T[sub 4]. All patients were monitored by sensitive thyroid-stimulating hormone, free triiodothyronine and free thyroxine assays throughout the follow-up. Nineteen healthy (12 premenopausal and 7 postmenopausal) matched women served as controls. In all subjects bone turnover was evaluated by the measurement of global skeletal uptake of technetium-99m methylene diphosphonate (GSU); bone mineral density (BMD) was measured by quantitative computed tomography at the lumbar spine (LS) and by dual-energy X-ray absorptiometry both at the LS and at three femoral sites: the femoral neck, Ward's triangle and the greater trochanter. No significant difference... [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index